Abstract | OBJECTIVES: To compare the efficacy of a 4-week ofloxacin-containing regimen and the standard WHO-MDT regimen for PB leprosy, in terms of the rate and timing of relapse after treatment completion. DESIGN: 124 PB patients were enrolled in a randomised, double-blind trial. Of these, 66 received the standard 6-month WHO-MDT regimen, whereas 58 received 28 daily supervised doses of rifampicin 600mg + ofloxacin 400 mg, plus 5 months of placebo. Patients were regularly monitored for clinical response and for signs of relapse after treatment completion. RESULTS: Patients enrolled in the ofloxacin group had a mean follow-up of 10.8 years (628 patient-years) with 1 early relapse at 3 years after treatment completion. On relapse, this patient remained smear negative but was reclassified by current WHO criteria (> or =6 skin lesions) as multibacillary (MB). Patients on the WHO-MDT regimen had a mean follow-up of 11.3 years (749 patient-years) with two late relapses at 8 and 12 years, both still classified as PB on relapse. CONCLUSION: In conclusion, both regimens appeared generally efficacious, and, in particular, resulted in few relapses.
|
Authors | Marivic F Balagon, Roland V Cellona, Rodolfo M Abalos, Robert H Gelber, Paul R Saunderson |
Journal | Leprosy review
(Lepr Rev)
Vol. 81
Issue 1
Pg. 27-33
(Mar 2010)
ISSN: 0305-7518 [Print] England |
PMID | 20496567
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Leprostatic Agents
- Dapsone
- Ofloxacin
- Rifampin
|
Topics |
- Adult
- Dapsone
(therapeutic use)
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Humans
- Leprostatic Agents
(therapeutic use)
- Leprosy, Paucibacillary
(drug therapy)
- Male
- Middle Aged
- Ofloxacin
(therapeutic use)
- Recurrence
- Rifampin
(therapeutic use)
- Skin
(microbiology)
- Time Factors
- Treatment Outcome
- World Health Organization
|